The Technical Analyst
Cocrystal Pharma Inc [COCP]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-6.51% $0.516
Last updated: 21 Jan 2022 @ 12:47 pm
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 50.27 mill |
| EPS: | -0.147 |
| P/E: | 0.000 |
| Earnings Date: | Mar 15, 2022 |
| SharesOutstanding: | 97.47 mill |
| Avg Daily Volume: | 0.833 mill |
| RATING 2022-01-20 |
|---|
| B+ |
| Buy |
| RATING DETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-08-20 | Pfenniger Richard C Jr | Buy | 40 000 | Common Stock |
| 2021-07-16 | Martin James Joseph | Buy | 250 000 | Stock Options (Right to Buy) |
| 2021-07-16 | Frost Phillip Md Et Al | Buy | 65 000 | Stock Options (Right to Buy) |
| 2021-07-16 | Pfenniger Richard C Jr | Buy | 50 000 | Stock Options (Right to Buy) |
| 2021-07-16 | Kornberg Roger D. | Buy | 65 000 | Stock Options (Right to Buy) |
| INSIDER POWER |
|---|
| 30.44 |
| Last 92 transactions |
| Buy: 453 925 162 | Sell: 59 808 344 |
Forecast:
14:19 - $0.514
Live Trading Signals (every 1 min)
Forecast 1: 12:49 - $0.518
Forecast 2: 13:39 - $0.523
Forecast 3: 14:19 - $0.514
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.0b
Last version updated: Wed 15th Dec 2021
Last version updated: Wed 15th Dec 2021
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.516 (-6.51% ) |
| Volume | 0.382 mill |
| Avg. Vol. | 0.833 mill |
| % of Avg. Vol | 45.86 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For COCP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
| Date | Signal | @ | Closed | % | Jan 21 - 17:25 | sell | $0.516 | N/A | Active |
|---|
COCP
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. The company is headquartered in Bothell, Washington and currently employs 10 full-time employees. The firm focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The firm focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C, influenza and norovirus. The firm uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The firm is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.
Latest Press Releases
2022-01-06 08:00:00 - Press Release
Cocrystal Pharma Receives Fda Guidance To Advance Clinical Development Of Its Covid-19 Antiviral Cdi-45205
Response to pre-ind briefing package supports pathway to initiating a phase 1 clinical study in 2022
2021-12-22 08:00:00 - Press Release
Cocrystal Pharma's Covid-19 Oral And Intranasal/pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against The Sars-cov-2 Omicron Variant
Antiviral activity now confirmed against sars-cov-2 and all variants of concern including omicron, delta, alpha, beta and gamma
2021-12-02 08:00:00 - Press Release
Cocrystal Pharma To Discuss Progress With Covid-19 Antiviral Programs And Clinical Strategy During Noble Capital Markets' Channelchek Virtual Roadshow
Bothell, wash., dec. 02, 2021 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”) announces that president and interim ceo sam lee, ph.d. and cfo and interim ceo james martin will present a company overview in the noble capital markets virtual roadshow series presented by channelchek. the live presentation will be by webcast on wednesday, december 8, 2021 at 1:00 p.m. eastern time (10:00 a.m. pacific time). registration for the webcast presentation is available here.
2021-12-01 16:05:00 - Press Release
Cocrystal Pharma Presents Preclinical Data From Covid-19 Antiviral Programs And Outlines Near-term Clinical Plans At The World Antiviral Congress 2021
Unveils designs for phase 1 and 2 stud ies with intranasal/pulmonary and oral sars-cov-2 protease inhibitors ; trial initiations expected in 2022
2021-11-08 08:00:00 - Press Release
Cocrystal Pharma's Sars-cov-2 Main Protease Inhibitors Demonstrate Pan-viral Activity Against Human Common Coronaviruses, Noroviruses, Rhinoviruses, And Enteroviruses
Bothell, wash., nov. 08, 2021 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”) announces that its sars-cov-2 main protease inhibitors showed potent in vitro pan-viral activity against human common coronaviruses, rhinoviruses, and respiratory enteroviruses that frequently cause the common cold, as well as against noroviruses that can cause symptoms of acute gastroenteritis. these protease inhibitors were discovered using the company's proprietary structure-based drug discovery technology and are currently being advanced by cocrystal toward clinical development to combat sars-cov-2 and its variants.
Latest News
2021-12-08 13:20:18 - PennyStocks
4 Biotech Penny Stocks to Watch With New Catalysts
These biotech penny stocks could be worth watching after recent announcements The post 4 Biotech Penny Stocks to Watch With New Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-11-15 13:55:13 - Zacks Investment Research
Cocrystal Pharma, Inc. (COCP) Reports Q3 Loss, Lags Revenue Estimates
Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-11-08 16:06:16 - Zacks Investment Research
Will Cocrystal Pharma, Inc. (COCP) Report Negative Q3 Earnings? What You Should Know
Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2021-11-01 19:24:29 - Benzinga
Cocrystal Pharma Files To Start Human Trial For Protease Inhibitor In COVID-19
Cocrystal Pharma Inc (NASDAQ: COCP) has submitted a pre-Investigational New Drug (IND) briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205 in COVID-19. FDA's response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 trials for CDI-45205.
2021-10-14 08:00:00 - GlobeNewsWire
Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021
BOTHELL, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza, hepatitis C viruses and noroviruses, announces that management will present at the Dawson James 2021 Small Cap Growth Conference on Thursday, October 21, 2021 at 2:00 p.m. Eastern time (10:00 a.m. Pacific time). The conference is being held at the Wyndham Grand Hotel in Jupiter, Fla.
2021-10-06 08:49:00 - GlobeNewsWire
Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza
BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza, hepatitis C viruses and noroviruses, announces receipt of clearance from an Australian Human Research Ethics Committee (HREC) to initiate a Phase 1 trial with its orally administered PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A.
2021-08-25 10:53:29 - PennyStocks
5 Best Penny Stocks To Buy Right Now According To Insiders
5 Penny Stocks Insiders Are Buying Right Now The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-08-16 10:41:08 - Zacks Investment Research
Cocrystal Pharma, Inc. (COCP) Reports Q2 Loss, Misses Revenue Estimates
Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-07-29 16:47:15 - Zacks Investment Research
Will Cocrystal Pharma, Inc. (COCP) Report Negative Q2 Earnings? What You Should Know
Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2021-07-29 10:10:35 - Benzinga
Cocrystal Pharma Stock Is Trading Higher After COVID-19 Candidate Shows Preclinical Activity Against Delta, Gamma Variants
Cocrystal Pharma Inc (NASDAQ: COCP) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants. "Our next steps are to scale-up synthesis and manufacture active pharmaceutical ingredient (API) to support Investigational New Drug (IND)-enabling studies to advance CDI-45205 into clinical trials," said James Martin, CFO, and interim co-CEO.